Collegium Cash And Short Term Investments vs Retained Earnings Analysis
COLL Stock | USD 30.42 0.27 0.90% |
Collegium Pharmaceutical financial indicator trend analysis is way more than just evaluating Collegium Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Collegium Pharmaceutical is a good investment. Please check the relationship between Collegium Pharmaceutical Cash And Short Term Investments and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
Cash And Short Term Investments vs Retained Earnings
Cash And Short Term Investments vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Collegium Pharmaceutical Cash And Short Term Investments account and Retained Earnings. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Collegium Pharmaceutical's Cash And Short Term Investments and Retained Earnings is -0.7. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Collegium Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Collegium Pharmaceutical's Cash And Short Term Investments and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Collegium Pharmaceutical are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Cash And Short Term Investments i.e., Collegium Pharmaceutical's Cash And Short Term Investments and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.7 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Collegium Pharmaceutical balance sheet. This account contains Collegium Pharmaceutical investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Collegium Pharmaceutical fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Collegium Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Collegium Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.At this time, Collegium Pharmaceutical's Tax Provision is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.37 this year, although the value of Selling General Administrative will most likely fall to about 97.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 21.0M | 63.2M | 83.3M | 87.5M | Depreciation And Amortization | 68.9M | 134.4M | 149.3M | 156.7M |
Collegium Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Collegium Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Collegium Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 306.3M | 643.8M | 692.1M | 1.2B | 1.1B | 1.2B | |
Short Long Term Debt Total | 21.6M | 266.6M | 258.8M | 872.8M | 674.3M | 708.0M | |
Other Current Liab | 153.1M | 178.7M | 222.2M | 261.2M | 264.9M | 278.1M | |
Total Current Liabilities | 197.3M | 191.2M | 230.4M | 270.1M | 457.9M | 480.8M | |
Total Stockholder Equity | 87.4M | 186.0M | 202.9M | 194.8M | 195.4M | 127.6M | |
Property Plant And Equipment Net | 20.9M | 27.4M | 27.1M | 26.4M | 22.0M | 13.8M | |
Net Debt | (148.4M) | 92.5M | 72.3M | 699.1M | 435.3M | 457.1M | |
Retained Earnings | (359.9M) | (333.1M) | (256.3M) | (281.3M) | (233.2M) | (244.8M) | |
Accounts Payable | 39.7M | 10.0M | 4.2M | 3.5M | 8.7M | 14.2M | |
Cash | 170.0M | 174.1M | 186.4M | 173.7M | 238.9M | 146.7M | |
Non Current Assets Total | 50.6M | 366.0M | 376.5M | 754.1M | 605.7M | 636.0M | |
Non Currrent Assets Other | 178K | 2.7M | 87K | 100K | 825.0K | 478.3K | |
Other Assets | 178K | 11.1K | 942.7M | 19.3M | 22.2M | 21.1M | |
Long Term Debt | 7.7M | 209.6M | 201.6M | 538.5M | 483.8M | 508.0M | |
Cash And Short Term Investments | 170.0M | 174.1M | 186.4M | 173.7M | 310.5M | 326.1M | |
Common Stock Total Equity | 34K | 35K | 36K | 37K | 42.6K | 29.4K | |
Common Stock Shares Outstanding | 33.5M | 35.2M | 41.0M | 33.8M | 41.8M | 30.1M | |
Liabilities And Stockholders Equity | 306.3M | 643.8M | 692.1M | 1.2B | 1.1B | 1.2B | |
Non Current Liabilities Total | 21.6M | 266.6M | 258.8M | 709.2M | 490.0M | 514.5M | |
Other Current Assets | 141K | 4.8M | 5.9M | 16.7M | 93K | 88.4K | |
Other Stockholder Equity | 447.3M | 519.1M | 459.2M | 476.1M | 428.6M | 366.6M | |
Total Liab | 218.9M | 457.8M | 489.1M | 979.3M | 947.9M | 995.3M | |
Property Plant And Equipment Gross | 20.9M | 27.4M | 27.1M | 26.4M | 31.7M | 33.3M | |
Total Current Assets | 255.7M | 277.9M | 315.5M | 420.0M | 537.6M | 564.5M | |
Accumulated Other Comprehensive Income | (1.7M) | (1.8M) | (2.3M) | 0.0 | 14K | 14.7K | |
Short Term Debt | 4.5M | 49.0M | 50.0M | 164.7M | 184.3M | 193.5M | |
Common Stock | 34K | 35K | 36K | 37K | 38K | 30.5K | |
Property Plant Equipment | 20.9M | 19.0M | 19.5M | 19.5M | 22.4M | 23.6M | |
Net Tangible Assets | 57.9M | (149.9M) | (65.8M) | (506.3M) | (455.7M) | (432.9M) | |
Net Receivables | 73.0M | 83.3M | 105.8M | 183.1M | 179.5M | 188.5M | |
Inventory | 9.6M | 15.6M | 17.4M | 46.5M | 32.3M | 33.9M | |
Short Long Term Debt | 3.8M | 47.5M | 48.4M | 162.5M | 183.3M | 192.5M | |
Intangible Assets | 29.5M | 335.9M | 268.7M | 567.5M | 421.7M | 442.8M | |
Retained Earnings Total Equity | (359.9M) | (333.1M) | (256.3M) | (281.3M) | (253.2M) | (265.9M) | |
Long Term Debt Total | 7.7M | 209.6M | 201.6M | 538.5M | 619.2M | 650.2M | |
Capital Surpluse | 447.3M | 519.1M | 502.1M | 538.1M | 618.8M | 468.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.